Disc Medicine Reports Fourth Quarter and Full Year 2024 Results, Advances Pipeline Initiatives

Disc Medicine, Inc. (NASDAQ: IRON) today issued its financial results for the fourth quarter and full year ended December 31, 2024, along with a detailed corporate update, in a Form 8-K filing with the Securities and Exchange Commission. The filing, dated February 27, 2025, accompanies a press release (Exhibit 99.1) that highlights key developments in the company’s clinical-stage biopharmaceutical programs and its strong financial position.

The press release notes that the company is on track to submit a new drug application (NDA) for bitopertin, under an accelerated approval pathway, targeting patients with erythropoietic protoporphyria (EPP) in the second half of 2025. In addition, Disc Medicine is preparing for the initiation of its APOLLO post-marketing confirmatory trial by mid-2025. The update detailed clinical progress across multiple programs, including positive Phase 1b data for DISC-0974 in patients with anemia related to myelofibrosis (MF) and non-dialysis-dependent chronic kidney disease (NDD-CKD), with further data expected in H2 2025. The Company further showcased first-in-human single and multiple ascending dose data from its Phase 1 trial of DISC-3405, which demonstrated proof-of-mechanism, with plans to initiate a Phase 2 study in polycythemia vera during the first half of 2025.

Financially, Disc Medicine reported a robust balance sheet enhanced by approximately $490 million in cash, cash equivalents, and marketable securities as of December 31, 2024. The Company’s liquidity was further bolstered by net proceeds of approximately $259 million from an underwritten public offering completed in January 2025, positioning it to fund operations into 2028. Despite a full year net loss of $109.4 million—up from $76.4 million in the prior year—increased research and development expenses (rising from $69.3 million to $96.7 million) and higher selling, general and administrative expenses were noted as investments to advance its pipeline.

John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, stated that 2024 was a transformative year for the company, emphasizing milestones achieved in the bitopertin program and the advancement of other pipeline candidates addressing serious hematological diseases. Quisel highlighted how the positive clinical data and secured funding further strengthen the company’s commitment to delivering potentially life-altering therapies to patients with high unmet medical needs.

With several key clinical trials expected to begin or report additional data in the upcoming months, Disc Medicine’s progress reflects its ongoing focus on leveraging its iron homeostasis portfolio to address a spectrum of hematologic conditions. The recent corporate and clinical updates underscore Disc Medicine’s strategic direction as it moves toward regulatory submissions and broader clinical evaluations in 2025.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Gemini Therapeutics’s 8K filing here.

Gemini Therapeutics Company Profile

Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.